惡性腫瘤已成為全球第二大死亡原因，藥物治療是腫瘤治療的重要手段之一。隨著腫瘤治療理念和臨床實(shí)踐的快速推進(jìn)，抗腫瘤藥物已經(jīng)不只局限于傳統(tǒng)的細(xì)胞毒性藥物，以細(xì)胞受體、關(guān)鍵基因調(diào)控分子為靶點(diǎn)的新型抗腫瘤藥物已應(yīng)用于臨床；在應(yīng)用上，藥品說明書往往滯后于臨床實(shí)踐，嚴(yán)格遵循藥品說明書中的傳統(tǒng)用法已無法滿足腫瘤治療實(shí)踐的需求，一些具有高級(jí)別循證醫(yī)學(xué)證據(jù)的用法未能及時(shí)在藥品說明書中明確規(guī)定。因此，在充分理論和實(shí)踐證據(jù)支持的基礎(chǔ)上對(duì)抗腫瘤藥物超說明書用法、含新型抗腫瘤藥物聯(lián)合用法以及妊娠期癌癥用藥等特殊用法進(jìn)行綜述，以期為臨床規(guī)范用藥提供參考。

Malignant tumor has become the second leading cause of death in the world and drug therapy is one of the important means of tumor treatment. With the rapid development of tumor therapy concept and clinical practice, anti-tumor drugs are not limited to traditional cytotoxic drugs. New anti-tumor drugs targeting cell receptors and key gene regulatory molecules have been applied in clinical practice. Drug instructions often lag behind clinical practice. The traditional usage of drug instructions can no longer meet the needs of oncology treatment practice and some usages with high level evidence-based medicine evidence are not clearly stipulated in drug instructions in time. Therefore, on the basis of sufficient theoretical and practical evidence support, the off-label use of anti-tumor drugs, the combined use of new anti-tumor drugs, and the special use of cancer drugs in pregnancy were reviewed in order to provide reference for rational drug use.

R979.1